Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.

Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR.

J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):467-70. Epub 2007 Oct 2.

PMID:
17911185
2.

Aceruloplasminaemia: a rare but important cause of iron overload.

Doyle A, Rusli F, Bhathal P.

BMJ Case Rep. 2015 May 14;2015. pii: bcr2014207541. doi: 10.1136/bcr-2014-207541. Review.

3.

Central nervous system involvement in a rare genetic iron overload disorder.

Bethlehem C, van Harten B, Hoogendoorn M.

Neth J Med. 2010 Oct;68(10):316-8.

4.

Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.

Suzuki Y, Yoshida K, Aburakawa Y, Kuroda K, Kimura T, Terada T, Kono S, Miyajima H, Yahara O.

Intern Med. 2013;52(13):1527-30. Epub 2013 Jul 1.

5.

Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation.

Finkenstedt A, Wolf E, Höfner E, Gasser BI, Bösch S, Bakry R, Creus M, Kremser C, Schocke M, Theurl M, Moser P, Schranz M, Bonn G, Poewe W, Vogel W, Janecke AR, Zoller H.

J Hepatol. 2010 Dec;53(6):1101-7. doi: 10.1016/j.jhep.2010.04.039. Epub 2010 Aug 4.

6.

Aceruloplasminaemia: a family with a novel mutation and long-term therapy with deferasirox.

Lindner U, Schuppan D, Schleithoff L, Habeck JO, Grodde T, Kirchhof K, Stoelzel U.

Horm Metab Res. 2015 Apr;47(4):303-8. doi: 10.1055/s-0034-1383650. Epub 2014 Aug 4.

PMID:
25089372
7.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
8.

Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

Mariani R, Arosio C, Pelucchi S, Grisoli M, Piga A, Trombini P, Piperno A.

Gut. 2004 May;53(5):756-8.

9.

Iron chelation therapy in myelodysplastic syndrome - Cui bono?

Tefferi A, Stone RM.

Leukemia. 2009 Aug;23(8):1373. doi: 10.1038/leu.2009.39. No abstract available.

PMID:
19672273
10.

Chelation therapy for iron overload.

Barton JC.

Curr Gastroenterol Rep. 2007 Mar;9(1):74-82. Review.

PMID:
17335681
11.

Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations.

Bosio S, De Gobbi M, Roetto A, Zecchina G, Leonardo E, Rizzetto M, Lucetti C, Petrozzi L, Bonuccelli U, Camaschella C.

Blood. 2002 Sep 15;100(6):2246-8.

12.

Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.

Lee SE, Yahng SA, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW.

Acta Haematol. 2013;129(2):72-7. doi: 10.1159/000342772. Epub 2012 Nov 15.

PMID:
23154600
15.

[Iron overload and iron chelation therapy in transfusion-dependent patients].

Suzuki T.

Nihon Rinsho. 2008 Mar;66(3):563-8. Review. Japanese.

PMID:
18326327
16.

Monitoring and treatment of iron overload: state of the art and new approaches.

Porter JB.

Semin Hematol. 2005 Apr;42(2 Suppl 1):S14-8. Review. No abstract available.

PMID:
15846580
17.

Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.

Porter JB, Shah FT.

Hematol Oncol Clin North Am. 2010 Dec;24(6):1109-30. doi: 10.1016/j.hoc.2010.08.015. Review.

PMID:
21075283
18.

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Fischer R, Piga A, Harmatz P, Nielsen P.

Ann N Y Acad Sci. 2005;1054:350-7. Review.

PMID:
16339683
19.

Iron chelation therapy in MDS: what have we learnt recently?

Schmid M.

Blood Rev. 2009 Dec;23 Suppl 1:S21-5. doi: 10.1016/S0268-960X(09)70006-2. Review.

PMID:
20116636
20.

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.

Ann Hematol. 2010 Feb;89(2):147-54. doi: 10.1007/s00277-009-0794-7. Epub 2009 Aug 19.

PMID:
19690857

Supplemental Content

Support Center